Treatable traits in the NOVELTY study

被引:39
|
作者
Agusti, Alvar [1 ,2 ,3 ,4 ]
Rapsomaniki, Eleni [5 ]
Beasley, Richard [6 ]
Hughes, Rod [7 ]
Mullerova, Hana [8 ]
Papi, Alberto [9 ,10 ]
Pavord, Ian D. [11 ,12 ]
van den Berge, Maarten [13 ]
Faner, Rosa [3 ,4 ]
机构
[1] Univ Barcelona, Catedra Salut Resp, Barcelona, Spain
[2] Hosp Clin Barcelona, Resp Inst, Serv Pneumol, Barcelona, Spain
[3] Inst Invest Biomed August Pi i Sunyer IDIBAPS, Barcelona, Spain
[4] CIBER Enfermedades Resp, Barcelona, Spain
[5] AstraZeneca, BioPharmaceut Med, Cambridge, England
[6] Med Res Inst New Zealand, Wellington, New Zealand
[7] AstraZeneca, BioPharmaceut Med, External Sci Engagement, Cambridge, England
[8] AstraZeneca, BioPharmaceut Med, Resp & Immunol, Med & Payer Evidence Strategy, Cambridge, England
[9] Univ Ferrara, Med Sch, Dept Resp Med, Ferrara, Italy
[10] Univ Hosp, Emergency Dept, Resp Unit, Ferrara, Italy
[11] Univ Oxford, Nuffield Dept Med, Oxford Resp NIHR BRC, Oxford, England
[12] Univ Oxford, Nuffield Dept Med, Resp Med Unit, Oxford, England
[13] Med Ctr Groningen, Dept Pulm Dis, Groningen, Netherlands
关键词
airways; allergy; asthma; bronchitis; chronic obstructive pulmonary disease; COPD; emphysema; smoking; RANDOMIZED CONTROLLED-TRIALS; EXTERNAL VALIDITY; REAL-LIFE; ASTHMA; DISEASE; BRONCHIECTASIS; MEDICINE; COPD;
D O I
10.1111/resp.14325
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background and objective Asthma and chronic obstructive pulmonary disease (COPD) are two prevalent and complex diseases that require personalized management. Although a strategy based on treatable traits (TTs) has been proposed, the prevalence and relationship of TTs to the diagnostic label and disease severity established by the attending physician in a real-world setting are unknown. We assessed how the presence/absence of specific TTs relate to the diagnosis and severity of 'asthma', 'COPD' or 'asthma + COPD'. Methods The authors selected 30 frequently occurring TTs from the NOVELTY study cohort (NOVEL observational longiTudinal studY; NCT02760329), a large (n = 11,226), global study that systematically collects data in a real-world setting, both in primary care clinics and specialized centres, for patients with 'asthma' (n = 5932, 52.8%), 'COPD' (n = 3898, 34.7%) or both ('asthma + COPD'; n = 1396, 12.4%). Results The results indicate that (1) the prevalence of the 30 TTs evaluated varied widely, with a mean +/- SD of 4.6 +/- 2.6, 5.4 +/- 2.6 and 6.4 +/- 2.8 TTs/patient in those with 'asthma', 'COPD' and 'asthma + COPD', respectively (p < 0.0001); (2) there were no large global geographical variations, but the prevalence of TTs was different in primary versus specialized clinics; (3) several TTs were specific to the diagnosis and severity of disease, but many were not; and (4) both the presence and absence of TTs formed a pattern that is recognized by clinicians to establish a diagnosis and grade its severity. Conclusion These results provide the largest and most granular characterization of TTs in patients with airway diseases in a real-world setting to date.
引用
收藏
页码:929 / 940
页数:12
相关论文
共 50 条
  • [1] Adding some NOVELTY to treatable traits
    Gibson, Peter G.
    RESPIROLOGY, 2022, 27 (11) : 912 - 913
  • [2] Treatable traits in the NOVELTY study: assessing complexity by network analysis
    Faner, Rosa
    Rapsomaniki, Eleni
    Beasley, Richard
    Hughes, Rod
    Mullerova, Hana
    Papi, Alberto
    Pavord, Ian D.
    Agusti, Alvar
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [3] Rosa Faner for the NOVELTY Study Investigators. Treatable traits in the NOVELTY study (vol 27, pg 929, 2022)
    Agusti, Alvar
    Rapsomaniki, Eleni
    Beasley, Richard
    Hughes, Rod
    Mullerova, Hana
    Papi, Alberto
    Pavord, Ian D.
    van den Berge, Maarten
    Faner, Rosa
    RESPIROLOGY, 2022,
  • [4] Treatable traits in the NOVELTY study: prevalence, patterns and relationship with physician-assessed severity
    Agusti, Alvar
    Rapsomaniki, Eleni
    Beasley, Richard
    Hughes, Rod
    Mullerova, Hana
    Papi, Alberto
    Pavord, Ian D.
    Faner, Rosa
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [5] Treatable traits in bronchiectasis
    Boaventura, Rita
    Sibila, Oriol
    Agusti, Alvar
    Chalmers, James D.
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52 (03)
  • [6] Treatable Traits in Systemic Sclerosis
    Amati, Francesco
    Bongiovanni, Gabriele
    Tonutti, Antonio
    Motta, Francesca
    Stainer, Anna
    Mangiameli, Giuseppe
    Aliberti, Stefano
    Selmi, Carlo
    De Santis, Maria
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2023, 65 (02) : 251 - 276
  • [7] Triaging treatable traits in asthma
    Baggott, Christina
    Beasley, Richard
    RESPIROLOGY, 2019, 24 (01) : 5 - 6
  • [8] Treatable traits in asthmatic children
    Vocos, Magdalena
    Donth Leger, Gimena
    Velasco, Carlos
    Flores, Tania
    Primerose, Doris
    Roque, Marcela
    Giubergia, Veronica
    Aguerre, Veronica
    Lucero, Belen
    Pelaez, Gabriela
    Manuel Figueroa, Juan
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [9] Treatable traits in COPD patients
    Nucera, Francesco
    Bianco, Andrea
    David, Teresa
    Salvato, Ilaria
    Adcock, Ian M.
    Caramori, Gaetano
    MINERVA MEDICA, 2022, 113 (03) : 449 - 459
  • [10] Genomics of Treatable Traits in Asthma
    Espuela-Ortiz, Antonio
    Martin-Gonzalez, Elena
    Poza-Guedes, Paloma
    Gonzalez-Perez, Ruperto
    Herrera-Luis, Esther
    GENES, 2023, 14 (09)